Results 61 to 70 of about 19,999 (193)
Hematology Reports, 2018 Thrombopoietin (TPO) is a critical regulator of hematopoiesis. We previously reported that a severe aplastic anemia (SAA) who received a short-term administration of pegylated recombinant human megakaryocyte growth and development factor (rHuMGDF).
Maho Ishikawa +6 more
doaj +1 more source
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Background Moderate‐to‐severe thrombocytopenia (platelet count < 100 × 109/L) occurs in fewer than 1% of pregnancies, posing management challenges, particularly surrounding eligibility for neuraxial anesthesia. Although recent anesthesia guidelines recommend a platelet threshold ≥ 70 × 109/L, outcomes data applying these recommendations in ...
Mackenzie E. Lemieux, Ming Y. Lim
wiley +1 more source
Thrombopoietin: The Novel Hepatic Hormone
, 2002 The glycoprotein thrombopoietin (TPO) is the major stimulator of megakaryopoiesis and platelet production. Hepatocytes express TPO mRNA at a constant rate.
Wolfgang Jelkmann, Eva-Maria Wolber
core +1 more source
Persistent Immune Thrombocytopenia as a Post‐Acute Sequelae of COVID‐19: A Case Report
Public Health Challenges, Volume 5, Issue 4, December 2026.ABSTRACT Immune thrombocytopenia (ITP) is a recognized hematologic complication associated with coronavirus disease 2019 (COVID‐19), but its persistence years after acute infection remains uncommon. We present a case of a 52‐year‐old male who was diagnosed with COVID‐19 in June 2020. Following recovery from the acute illness, he had persistent fatigue,
Riazullah +5 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 11, Page 2836-2852, November 2026.ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas +4 more
wiley +1 more source
Idiopathic thrombocytopenic purpura: laboratory diagnosis and management
Universa Medicina, 2016 Idiopathic thrombocytopenic purpura (ITP) or immune thrombocytopenic purpura is a disease characterized by low platelet count (
Alvina Alvina
doaj +1 more source
Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome
ACR Open Rheumatology, Volume 8, Issue 10, October 2026.Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors
Daniel Montes +15 more
wiley +1 more source
THROMBOPOIETIN RECEPTOR FRAGMENTS AND USES THEREOF
, 2023 The present invention relates to a polypeptide comprising fragments of the extracellular domain of thrombopoietin receptor, a fusion protein and a pharmaceutical composition comprising said polypeptide, and uses ...
UNIVERSITE CATHOLIQUE DE LOUVAIN +3 more
core
American Journal of Hematology, Volume 101, Issue 10, Page 2520-2532, October 2026.ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano +52 more
wiley +1 more source